Gilead has invested heavily in oncology over the last several years, using a string of deals to amass a portfolio of cancer ...

The company reiterated its financial outlook for the year but is struggling to predict the likely impact of pharmaceutical ...

Halozyme claims Merck infringed on patents in developing a subcutaneous form of Keytruda. Elsewhere, Vanda’s challenge to an ...

The CRISPR company is laying off about a third of its employees and stopping work on an experimental lupus treatment in a bid to focus resources on a pair of cancer cell therapies.

Net sales of Cobenfy, whose success is imperative for Bristol Myers, totaled $27 million in the first quarter, handily ...

The biotech is using AI and a trove of health data to better understand why certain conditions progress and intervene ...

The drugmaker absorbed additional tariff-related costs in the first quarter, but has taken steps to lower the financial impact it’ll have for the rest of the year and beyond.

The startup, Veraxa, has $253 million in cash and is raising a crossover funding round to support a pipeline of T cell ...

Repertoire Immune Medicines will get $35 million upfront, and possibly $730 million more, in a deal to help Roche’s Genentech ...

A spokesperson confirmed the Danish drugmaker has asked U.S. regulators to clear an oral version of its weight loss drug ...

The big pharma joined several of its peers in committing to invest billions of dollars in new and expanded manufacturing ...

The data could help the Enhertu regimen overtake a drug combination that’s been used as the initial treatment for ...